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Abstract: We report the synthesis, characterisation and cytotoxicity of six 
cyclometalated rhodium(III) complexes [CpXRh(C^N)Z]0/+, in which CpX = Cp*, Cpph, 
or Cpbiph, C^N = benzo[h]quinoline, and Z = chloride or pyridine. Three x-ray crystal 
structures showing the expected “piano-stool” configurations have been determined. 
The chlorido complexes hydrolysed faster in aqueous solution, also reacted 
preferentially with 9-ethyl guanine or glutathione compared to their pyridine analogues. 
The 1-biphenyl-2,3,4,5,-tetramethylcyclopentadienyl complex [CpbiphRh(benzo-
[h]quinoline)Cl] (3a) was the most efficient catalyst in coenzyme reduced nicotinamide 
adenine dinucleotide (NADH) oxidation to NAD+ and induced an elevated level of 
reactive oxygen species (ROS) in A549 human lung cancer cells. The pyridine 
complex [CpbiphRh(benzo[h]quinoline)py]+ (3b) was the most potent against A549 lung 
and A2780 ovarian cancer cell lines, being 5-fold more active than cisplatin towards 
A549 cells, and acted as a ROS scavenger. This work highlights a ligand-controlled 




The approval of cisplatin as an anticancer drug in the late 1970s has not only led to 
new generations of platinum drugs in clinical use (carboplatin and oxaliplatin) or trials, 
but also to the search for a new era of transition metal-based anticancer agents.[1-4] 
Group 9 metals iridium and rhodium have attracted much attention although are less 
widely studied than platinum.[5-8] IrIII and RhIII complexes with low spin d6 configurations 
are usually considered to be kinetically inert, however, recent studies have revealed 
that their reactivity toward biological targets can be adjusted by the rational selection 
of the surrounding ligands directly coordinated to the metal.[6,9] Kinetically stable 
iridium/rhodium pyridocarbazole complexes have been synthesized by Meggers and 
co-workers as potent enzyme inhibitors,[10-13] and Sheldrick and co-workers have 
reported various pentamethyl-cyclopentadienyl (Cp*) iridium/rhodium complexes with 
chelating polypyridine ligands as potent anticancer agents.[14] More recently, attention 
has turned to cyclometalated iridium and rhodium complexes in which five-membered 
chelate rings contain a strong M-C  bond.[15,16] Nevertheless, research on 
cyclometalated rhodium complexes has largely focused on non-cyclopentadienyl 
cyclometalated rhodium complexes that target DNA, enzyme or protein-protein 
interfaces.[5,9,17-20] Reported cyclopentadienyl rhodium anticancer complexes to date, 
have mainly contained N^N,[21,22] N^S,[23] N^O,[24-26] or O^O[22,27,28] chelating ligands. 
Our recent work has demonstrated that replacing the N^N coordinating ligand 
2,2’-bipyridine or 1,10-phenanthroline with C^N chelating 2-phenylpyridne or 
benzo[h]quinoline in pentamethyl-cyclopentadienyl (Cp*) iridium complexes, not only 
enhances nucleobase binding and lipophilicity, but also switches on anticancer activity 
towards human A2780 ovarian cancer cells.[29,30] Moreover, the chelated iridium(III) 
biphenyl-tetramethyl-cyclopentadienyl complex [CpbiphIr(phenylpyridine)(pyridine)]+ 
can utilize NADH as a hydride source to transfer hydride electrons to oxygen, 
generating hydrogen peroxide and reactive oxygen species in cancer cells to trigger 
cell death.[31] Recently, we have described rhodium anticancer complexes 
[CpXRh(N^N’)Cl]+ (Cpx = Cp*, Cpph, or Cpbiph) which can be effective transfer 
hydrogenation catalysts inducing reductive stress when co-administrated with non-
toxic does of sodium formate as the hydride donor in cancer cells.[32] Intriguingly，the 
CpX ring in these catalytic [CpXRh(N^N’)Cl]+ (N^N’ is the bipyridine, dimethylbipyridine, 
or phenanthroline) complexes can be readily activated by deprotonation and undergo 
rapid deuteration in aqueous media, so providing a novel activation pathway for half-
sandwich Rh(III) complexes.[33] Based on these interesting discoveries, we have 
extended our studies to include cyclometalated cyclopentadienyl rhodium anticancer 
complexes with potential catalytic properties. 
Herein, six cyclometalated rhodium complexes (Scheme 1) bearing different 
cyclopentadienyl CpX rings with C^N chelating ligand benzo[h]quinoline have been 
synthesized and fully characterized by 1H NMR, 13C NMR, high resolution ESI-MS and 
elemental analysis. Five novel complexes 2a, 3a, 1b-3b are reported, and the X-ray 
crystal structures of complexes 2a, 3a and 1b·PF6 have been determined. Complexes 
1a-3a contain chloride, while complexes 1b-3b feature pyridine as the monodentate 
ligand. Their aqueous chemistry including hydrolysis, binding to nucleobase 9-
ethylguanine (9-EtG) or abundant cellular thiol glutathione (GSH, -L-Glu-L-Cys-Gly), 
as well as catalytic activity in the oxidation of coenzyme NADH are evaluated and 
compared. Cytotoxicity has been screened against human A549 lung and A2780 
ovarian cancer cell lines. Cellular Rh accumulation, ROS induction and apoptosis in 
A549 cancer cells induced by complexes 3a and 3b at equipotent concentrations have 
been investigated to elucidate their possible mechanism of action.  
 
 
Scheme 1. Structures of the six cyclometalated rhodium(III) benzo[h]quinoline 
complexes studied in this work. 
 
RESULTS AND DISCUSSION 
Synthesis and Characterization 
The synthesis of the rhodium dimers [CpXRh(µ-Cl)Cl]2 (CpX = Cpph, Cpbiph) followed 
the reported procedure.[32,34] The rhodium chloride complexes 1a-3a were synthesized 
via C-H activation of benzo[h[quinoline by the rhodium dimer aided by sodium acetate 
in dichloromethane at ambient temperature as reported previously.[35] In contrast, 
pyridine complexes 1b-3b were obtained in good yields through the reaction of the 
corresponding chloride complexes with silver nitrate and then with excess pyridine 
(Scheme 2). All complexes were characterized by 1H and 13C NMR, elemental analysis 
and high resolution ESI-MS.  
 
 
Scheme 2. Synthesis route for rhodium complexes containing chloride (1a-3a) and 
pyridine (1b-3b) ligands. 
 
X-ray crystal structures 
Crystal structures of [CpphRh(benzo[h]quinoline)Cl] (2a), 
[CpbiphRh(benzo[h]quinoline)Cl] (3a) and [Cp*Rh(benzo[h]quinoline)pyridine]PF6 
(1b·PF6) with PF6- as the counter anion were determined and are shown in Figure 1 
with the atom numbering scheme. Crystallographic data are listed in Table S1, and 
selected bond lengths and angles in Table S2. All structures adopt the familiar “piano-
stool” geometry. The distances between Rh and the centroid of the η5-
cyclopentadienyl ring are within 1.827-1.832 Å. The length of the Rh-C (quinoline) 
bond in 2a, 3a, 1b·PF6 [2.050(3), 2.0458(15), 2.058(2), respectively] is significantly 




Figure 1. X-ray structures with atom numbering of (a) [CpphRh(benzo[h]quinoline)Cl] 
(2a); (b) [CpbiphRh(benzo[h]quinoline)Cl] (3a); (c) [Cp*Rh(benzo[h]quinoline)- 
pyridine]PF6 (1b·PF6), drawn with thermal ellipsoids at 50% probability. Hydrogen 
atoms and counterions have been omitted for clarity. 
 
Aqueous solution chemistry 
The hydrolysis of these complexes was monitored by 1H NMR (Figures 2, S1, S2) as 
well as UV-vis spectroscopy at 310 K in methanol/water. Methanol was used to ensure 
the sufficient solubility of the complexes in water. All the chloride complexes showed 
faster hydrolysis than their pyridine counterparts. Their hydrolysis rates and half-lives 
of hydrolysis (listed in Table 1) were determined by fitting the UV-vis absorption 
changes versus time to pseudo-first-order kinetics (Figure S6). With the extension of 
Cp* to Cpph, to Cpbiph, the hydrolysis half-lives of the chloride complexes become 
shorter, while the hydrolysis half-lives of the pyridine complexes become longer. The 
hydrolysis extent over 24 h for chloride complexes 1a-3a was 43%-60% at equilibrium 
based on integration of 1H NMR peaks. In addition, after 24 h, an additional set of 1H 
NMR  peaks was visible for complexes 1a-3a which can be attributed to release of the 
benzo[h]quinoline ligand (ca. 25%), as characterized by 1H NMR, 1H-1H COSY and 
confirmed by ESI-MS with m/z 180.13 (calculated m/z 180.08) (Figure S7-S9). In 
contrast, after 24 h at 310 K, no apparent change was observed for millimolar solutions 
of the pyridine complexes 1b-3b in d4-MeOD/D2O (1/9-1/2 v/v) by 1H NMR (Figure S3-
S5), although the hydrolysis of micromolar solutions of complexes 1b-3b could be 
observed by UV-vis spectroscopy at 310 K (Figure S10). 
When 104 mM NaCl (to mimic the chloride concentration in blood plasma), was 
added to the 24 h equilibrium hydrolysis solution of complexes 1a (Figure 2c) and 2a 
(Figure S1c), peaks for the aqua adducts disappeared and those for the parent 
(b) (c)(a)
chloride complexes increased in intensity, confirming that hydrolysis of the chloride 
complexes is reversible. 
 
 
Figure 2. 400 MHz 1H NMR spectra of [Cp*Rh(benzo[h]quinoline)Cl] (1a) (ca. 0.5 mM) 
in d4-MeOH/D2O (v/v 4/1) after (a) 15 min; (b) 24 h; and (c) 10 min after addition of 
NaCl (104 mM). After 15 min, 60% of the parent complex 1a (■) hydrolysed to its aqua 
adduct [Cp*Rh(benzo[h]quinoline)D2O]+ (●). After 24 h, one third of the aqua adduct 
[Cp*Rh(benzo[h]quinoline)D2O]+ had decomposed into the free chelated ligand and 
[Cp*Rh(D2O)3]2+ (▲). After additon of NaCl, all the aqua adducts were coverted into 
1a, with the released ligand remaining unbound and the [Cp*Rh(D2O)3]2+ reacting with 
Cl- to form [Cp*RhCl2]2 (▲). 
 
Table 1. Hydrolysis data for complexes 1a-3a and 1b-3b at 310 K. 
 
[a]: Determined by 1H NMR in d4-MeOH/D2O. [b]: At equilibrium, determined by UV-
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Interaction with 9-EtG 
Reactions between chloride/pyridine complexes and nucleobase 9-ethylguanine (9-
EtG) were studied by 1H NMR spectroscopy. Equimolar 9-EtG was added to an 
equilibrium solution of [Cp*Rh(benzo[h]quinoline)Cl] (1a) in d4-MeOD/D2O (4/1, v/v, 
pH* 7.4) and the 1H NMR spectra showed that ca. 90 % of 1a had rapidly formed 
adducts with 9-EtG (within 20 min) based on the integral of the Cp* protons of 1a (δ 
1.71 ppm), aqua adducts of 1a (1.68 ppm) and 9-EtG adducts (δ 1.66 ppm) (Figure 3). 
The new singlet peak for H8 of the bound 9-EtG appeared at 7.39 ppm, shifted by 0.37 
ppm to high field relative to that of free 9-EtG. The ESI-MS of the final NMR solution 
showed a major peak at m/z 595.3, assignable as the adduct of 1a with 9-EtG [Cp*(Rh-
9-EtG)(benzo[h]quinoline)]+ (calcd m/z 595.1). Meanwhile, in the presence of 4 mM 
NaCl, 1a still showed a high affinity for 9-EtG with ca. 90% 1a binding to 9-EtG (Figure 
S11) at 310 K. Adducts of 2a and 3a with 9-EtG were also characterised by 1H NMR 
(Figure S12) and ESI-MS (Table S3). 
By contrast, a 1H NMR study of the pyridine complex 
[Cp*Rh(benzo[h]quinoline)py]NO3 (1b) with equimolar 9-EtG in d4-MeOD/D2O (1/4, v/v, 
pH* 7.4) showed that only 30% of complex 1b formed an adduct with 9-EtG after 24 h 
at 310 K (Figure 4) based on the integral of the Cp* methyl protons at 1.57 ppm (1b) 
and 1.56 ppm (9-EtG adduct with 1b). This new adduct of complex 1b with 9-EtG was 
also confirmed by ESI-MS by the peak at m/z 595.3 (calcd m/z 595.1). 
 
 
Figure 3. 300 MHz 1H NMR spectra of (a) equilibrium solution of ca. 1.0 mM complex 
[Cp*Rh(benzo[h]quinoline)Cl] (1a) in d4-MeOD/D2O (4/1 v/v, pH* 7.4), containing both 
the chloride complex 1a (■) and its aqua adduct (●). (b) 20 min after addition of 
equimolar 9-EtG, ca. 90% of 1a had formed an adduct (▲) with 9-EtG. 
 
(a) Hydrolysis equilibrium
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Figure 4. 300 MHz 1H NMR spectrum of ca. 2.6 mM complex 
[Cp*Rh(benzo[h]quinoline)py]+ (1b) (■) in d4-MeOD/D2O (v/v 1/4, pH* 7.4) with 




NADH is a crucial coenzyme in numerous biological catalytic processes. Previously, 
we have found that cyclopentadienyl iridium complexes bearing N^N coordinating 
ligands can accept the hydride from NADH and induce the reduction of protons to 
H2,[36] and quinones to semiquinones.[37] The 1-biphenyl-2,3,4,5,-
tetramethylcyclopentadienyl (Cpbiph) iridium complex with the C^N chelating 2-
phenylpyridine can also transfer hydride from NADH to oxygen to produce the  reactive 
oxygen species (ROS) hydrogen peroxide.[31] Therefore, the time dependence of 
reactions between rhodium complexes (0.8 µM) and NADH (75-144 µM) was studied 
over 24 h in 1.6% MeOH/98.4% phosphate buffer (5 mM, pH 7.4) by UV-vis 
spectroscopy at 310 K (Figure S13, S14). The reactions proceeded via first-order 
kinetics (Figure S15). 
The turnover number (TON) and turnover frequency (TOF) were determined 
based on the decrease in absorption of NADH at 339 nm due to conversion of NADH 
to NAD+. In reactions with NADH at a higher concentration (144 µM), pyridine 
complexes 1b-3b showed a much lower TOF than their respective chloride analogues 
1a-3a (Table 2). This might due to the decrease in hydrolysis of pyridine complexes 
compared to chloride analogues, as hydrolysis is believed to be the first step to interact 
with NADH.[31] In the presence of 75 µM or 117 µM NADH, respectively, complex 3a 
bearing a Cpbiph ring showed a ca. 2.3 x or ca. 2.6 x higher TOF than the other chloride 
complexes 1a and 2a. In contrast, in the presence of 144 µM NADH, pyridine complex 
1b, which has the fastest hydrolysis rate among all these pyridine complexes, 
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(appearance of blue colour on Quantofix test sticks) in the reaction mixture of complex 
3a (ca. 1 mM) with 3.5 mol equiv. NADH in MeOH/H2O (1/1 v/v) after 24 h at 310 K 
(Figure S16). 
 
Table 2. TONs and TOFs for rhodium complexes (0.8 µM) in the catalytic oxidation of 




Sodium formate as hydride donor 
Inspired by the ability of half-sandwich rhodium(III) complexes with N^N chelating 
ligands to act as transfer hydrogenation catalysts using sodium formate as an hydride 
source and convert pyruvate to lactate,[32] the ability of complex 
[Cp*Rh(benzo[h]quinoline)Cl] (1a) to reduce pyruvate to lactate was investigated. 
Upon addition of 10 mol equiv. sodium formate to a solution of 1a in d4-MeOD/H2O 
(99/1 v/v), the colour turned from orange to red. In the hydride region, a doublet 
appeared at -12.26 ppm (J(1H-103Rh) = 32 Hz, Figure S17) which can be assigned to 
the hydride complex [Cp*Rh(H)(benzo[h]quinoline)] in accord with the reported J 
value[38] for the same Rh-H species. Meanwhile, a triplet at -19.34 ppm (J = 24 Hz) 
was also observed in Figure S17. The J value of this triplet is characteristic of hydride 








75 13 1.16 ± 0.06 
117 49 3.35 ± 0.11 
2a 
75 14 1.10 ± 0.08 
117 51 3.38 ± 0.15 
3a 
75 32 2.85 ± 0.12 
117 58 7.58 ± 0.20 
1b 144 72 2.85 ± 0.06 
2b 144 35 1.63 ± 0.02 
3b 144 49 1.73 ± 0.04 
 
bond on the labile coordination site occupied by MeOD or H2O on another Rh molecule. 
Subsequently, when 5 mol equiv. pyruvate was added to this Rh-hydride solution, 
ca.17% of pyruvate (δ 2.36 ppm, singlet) was reduced to lactate (δ 1.32 ppm, doublet) 
based on 1H NMR peak integrals over 24 h at 310 K (Figure S18). 
 
Reactivity with GSH 
The abundant cellular tripeptide glutathione (GSH) is a detoxification agent and ROS 
scavenger. Reactions between complex [CpbiphRh(benzo[h]quinoline)Cl] (3a)/pyridine 
analogue [CpbiphRh(benzo[h]quinoline)py]+ (3b) and GSH were investigated. LC-MS 
analysis of 3b with 2 mol equiv. GSH in MeOH/H2O (1/9 v/v) revealed that most of the 
parent complex 3b remained intact within the first 30 min, but after 18 h, 3b was 
converted into dinuclear [(CpbiphRh)2(µ-SG)3]+ adducts (Figure S19). However, under 
the same conditions, the chloride complex 3a formed [CpbiphRh(SG)+H]+ as detected 
by ESI-MS with m/z 683.6 (calcd 683.6) as soon as it was mixed with GSH. These 
differences in reactions with GSH may have a significant effect on the anticancer 
activity of these two complexes. 
 
Cytotoxicity 
The anticancer activity of rhodium complexes against human A549 lung and A2870 
ovarian cancer cell lines was evaluated in vitro using the SRB assay after 24 h 
treatment and subsequent 72 h of cell recovery. The detailed half maximal inhibitory 
concentration (IC50) values are listed in Table S4 and shown in Figure 5. Compared to 
cisplatin (CDDP) as the positive control, chloride complexes 1a-3a and pyridine 
complexes 1b-2b all showed antiproliferative activity towards these two cell lines. In 
particular, the pyridine complex [CpbiphRh(benzo[h]quinoline)py]NO3 (3b) exhibited the 
highest activity among all screened rhodium complexes, ca. 5 x greater potency than 
cisplatin against A549 lung cancer cells.  
From the study of cyclopentadienyl iridium complexes with the C^N chelating 
ligand 2-phenylpyridine, the extension of CpX (from Cp* to Cpph to Cpbiph) greatly 
enhanced the anticancer activity perhaps due to the increased hydrophobicity 
facilitating passage through the cell membrane or to the extended phenyl or biphenyl 
ring which can intercalate between DNA bases.[40] Among the CpX analogues, Cpbiph 
capped complexes 3a and 3b were the most hydrophobic and exhibited the highest 
potency as expected. Moreover, pyridine complex 3b was ca. 2 x and ca. 10 x more 
potent than its chloride analogue 3a towards A2780 and A549 cancer cells, 
respectively (A2780: IC50 0.88 µM for 3b and 1.60 µM for 3a; A549: IC50 0.74 µM for 
3b and 7.69 µM for 3a). Therefore, despite the replacement of the chloride with 
pyridine decreasing hydrolysis, inhibiting adduct formation with 9-EtG/GSH and 
lowering the catalytic TOF, the in vitro anticancer activity of pyridine complexes was 
higher than that of chloride analogues, in line with the behaviour of cyclometalated 
iridium pyridine complexes which showed slower hydrolysis/less interaction with 
biomolecules, but higher potency than their chloride analogues.[31] 
 
 
Figure 5. Anticancer activity of rhodium complexes toward human A549 lung and 
A2780 ovarian cancer cells in comparison with cisplatin (CDDP). The values of half 
maximal growth inhibitory concentration (IC50) are determined by SRB assay and 
given as the mean ± standard deviations for three independent experiments. Stock 
solutions of tested complexes were prepared with 0.5% DMSO and the drug-treatment 
period was 24 h. 
 
Cellular Rh Accumulation  
Complexes [CpbiphRh(benzo[h]quinoline)Cl] (3a) and [CpbiphRh(benzo[h]quinoline)- 
py]NO3 (3b) bearing the Cpbiph ring, were the most potent candidates among the 
chloride family 1a-3a and pyridine family 1b-3b. However, complex 3b is positively 
charged and 10 x more potent than neutral complex 3a toward A549 cancer cells 
(Figure 5). Thus, to elucidate their different anticancer activities, the cellular 
accumulation of rhodium in A549 human lung cancer cells after 24 h treatment with 
complexes 3a and 3b at equipotent concentrations of 0.5 x and 1 x IC50 at 310 K was 
quantified by ICP-MS as shown in Figure 6 (values in Table S5). From Figure 6, the 
accumulation of Rh in the cells treated with complex 3a or 3b increased in a 
concentration-dependent manner. After 24 h the cellular Rh accumulation of chloride 
complex 3a was ca. 49-fold (at 0.5 x IC50) and ca. 59 fold (at 1 x IC50) higher than that 
of complex 3b.This significant difference correlates with the higher hydrophobicity of 
neutral complex 3a compared to the positive complex 3b, in contrast to the reported 
cyclometalated iridium complex [CpbiphIr(2-phenylpyridine)py]+ which was found to 
have 20-fold higher Ir accumulation than the neutral iridium complex [CpbiphIr(2-
phenylpyridine)Cl] in A2780 cancer cells.[31] 
 
 
Figure 6. Accumulation of Rh (ng/million cells) in A549 human lung cancer cells after 
24 h treatment with chloride complex 3a or pyridine complex 3b at concentrations of 
0.5 x IC50 and 1 x IC50. The values represent mean ± standard deviations for three 
independent samples. The asterisk denotes the p-values obtained by comparing each 
dataset with the negative control (untreated cells) using a t-test, *p < 0.05, **p < 0.01. 
 
ROS induction in A549 cancer cells 
The chloride complexes 1a-3a exhibited higher catalytic efficiency than pyridine 
analogues in the oxidation of NADH to NAD+ with production of hydrogen peroxide. 
We investigated whether these catalytic chloride complexes can induce a high level of 
reactive oxygen species (ROS) in A549 human lung cancer cells after 24 h treatment 
with complexes [CpbiphRh(benzo[h]quinoline)Cl] (3a) and [CpbiphRh(benzo[h]quinoline) 
-py]NO3 (3b) at concentrations of IC50 or 2 x IC50 by flow cytometry fluorescence 
analysis using a total ROS/Superoxide detection kit (Figure 7, details in Table S6). 




































peroxy and hydroxyl radicals, peroxynitrite, and NO species, but also the level of 
superoxide (SO). After 24 h drug treatment, a concentration-dependent ROS level 
modulation indicated by the fluorescence signals of FL1 (indicating the total ROS level) 
and FL2 (indicating the SO level) channels was observed: in cells treated with complex 
3a, the ROS+/SO+ cell population increased significantly from 18 ± 2 % at IC50 
concentration to 47 ± 2 % at 2 x IC50 concentration of complex. In contrast, for cells 
treated with complex 3b, the cell population producing ROS decreased significantly 
from 60 ± 2 % (ROS+/SO-)/22 ± 2 % (ROS+/SO+) by IC50 concentration treatment to 
38 ± 0.1 (ROS+/SO-)/10 ± 0.3 (ROS+/SO+) by 2 x IC50 concentration treatment, 
combined with an increase in the quadrant of ROS-/SO- from 17 ± 0.2 % to 51 ± 0.2 
(Figure 7, Table S6). This observation suggested opposing mechanisms of action for 




Figure 7. Flow cytometry plots of total ROS and superoxide production after 24 h 
treatment with 1× and 2× IC50 concentrations of complexes (a) 3a and (b) 3b. Cell 
population of total ROS and superoxide production after 24 h treatment with 1× and 
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standard deviations for three independent samples. The asterisk denotes the p-values 
obtained by comparing each dataset with the negative control (untreated cells) using 
a t-test, *p < 0.05, **p < 0.01, ap > 0.05. 
 
Apoptosis assay 
Apoptosis is well recognized as a distinct cell death mechanism in tumours responding 
to anticancer therapies.[41] To investigate whether apoptosis is involved in the 
anticancer activity , A549 cells were treated with [CpbiphRh(benzo[h]quinoline)Cl] (3a) 
and [CpbiphRh(benzo[h]quinoline)py]NO3 (3b) at their equipotent concentrations of IC50 
and 2 x IC50 for 24 h, then stained with FITC labelled-annexin V/propidium iodide (PI) 
and analysed by flow cytometry. This assay determined cell populations as early 
apoptosis (annexin V+/PI-, stained by annexin V only), late apoptosis (annexin V+/PI+, 
stained by annexin V and PI), necrosis (annexin V-/PI+, stained by PI only), and viable 
(annexin V-/PI-, unstained by annexin V and PI). No obvious induction of apoptosis by 
complex 3a or 3b was observed at their equipotent concentrations (Figure S20). 
However, there was a significant increase in necrotic cell population induced by the 
treatment with complex 3b at 2 x IC50 concentration (Table S7).  
 
CONCLUSIONS 
In summary, we have described the synthesis and characterization of novel 
cyclopentadienyl C^N chelated RhIII anticancer complexes. The reactivity and 
cytotoxicity of these complexes can be reasonably modulated by selection of the 
monodentate ligand as chloride or pyridine. The hydrolysis rate of chloride complexes 
increases in the order Cp*< Cpph < Cpbiph, showing that incorporation of the extended 
CpX ring confers more labile kinetics on the monodentate chloride ligand. On the 
contrary, when the chloride is replaced with pyridine, the rate of hydrolysis is slowed 
down by orders of magnitude and decreases in the order Cpbiph > Cpph > Cp*. This 
difference in hydrolysis kinetics for the chloride and pyridine complexes leads to the 
differences in reactivity, and subsequent differences in cytotoxicity.  
The pyridine complex 3b reacts more slowly with glutathione than the chloride 
analogue, resulting in less deactivation and an order of magnitude greater potency 
towards lung cancer cells. Meanwhile, complex 3b accumulates to a much lesser 
extent than the chloride analogue in cancer cells at equipotent IC50 concentrations, 
indicating that complex 3b requires a lower dose than 3a to achieve the same 
therapeutic potency. Significantly, the rhodium complexes studied here exhibit a 
different mechanism of action from cisplatin, which acts through interaction with DNA. 
The chloride complex 3a shows the greatest catalytic efficiency in NADH oxidation 
and induces a remarkable increase in the level of ROS in lung cancer cells. Whereas 
the pyridine complex 3b can act as a ROS scavenger, which is distinct from the related 
pyridine iridium complex [CpbiphIr(2-phenylpyridine)py]+ which induces a higher level 
of ROS in ovarian cancer cells.[31] Although the reason of the ROS scavenging activity 
is not clear, pyridine complex 3b is the first example of an organometallic rhodium 
complex with such a behaviour. Cyclometalated rhodium complexes such as these 
may provide a new generation of transition metal-based chemotherapeutic agents and 




Rhodium(III) trichloride hydrate was purchased from Precious Metals Online (PMO Pty 
Ltd.) and used as received. [Cp*Rh(µ-Cl)Cl]2, benzo[h]quinoline, silver nitrate, sodium 
formate, sodium pyruvate, β-nicotinamide adenine dinucleotide reduced disodium salt 
(NADH), and celite were purchased from Sigma-Aldrich. MeOD-d4, D2O, and CDCl3-
d1 for NMR spectroscopy and Quantofix® peroxides test sticks (1-100 mg/L range) 
were purchased from Sigma-Aldrich. Reduced glutathione was obtained from Alfa 
Aesar. Disodium hydrogen phosphate dihydrate, disodium hydrogen phosphate 
dodecahydrate, anhydrous sodium acetate, HPLC grade solvents (water and 
acetonitrile) with added trifluoroacetic acid with analytic grade, anhydrous 
DCM/pyridine and laboratory grade solvents used in syntheses were purchased from 
fisher scientific. A549 human lung and A2780 human ovarian cancer cell lines were 
purchased from the European Collection of Animal Cell Culture (ECACC, Salisbury, 
U.K.). Roswell Park Memorial Institute (RPMI-1640) medium, and phosphate-buffered 
saline (PBS) were purchased from PAA Laboratories GmbH. The total 
ROS/superoxide detection kit was purchased from Enzo Life Sciences. The apoptosis 
detection regents were purchased from Abcam. 
Synthesis 
The dimeric rhodium precursors [CpphRh(µ-Cl)Cl]2, [CpbiphRh(µ-Cl)Cl]2 and complex 
[Cp*Rh(benzo[h]quinoline)Cl] (1a) were synthesized according to the literature.[32,34,35]  
Synthesis of [CpXRh(benzo[h]quinoline)Cl] (2a and 3a)  
General procedure: [CpXRh(µ-Cl)Cl]2 (0.12 mmol) with benzo[h]quinoline (0.36 mmol) 
and anhydrous sodium acetate (0.98 mmol) in 20 ml anhydrous DCM was stirred 
under nitrogen 48 h. Then the solution was filtered through celite and purified by 10 g 
silica cartridge on Biotage (methanol/dichloromethane, 5/95 v/v). Then column-
purified powder was recrystallized from dichloromethane/diethyl ether at 277 K to give 
a red crystalline solid. 
[CpphRh(benzo[h]quinoline)Cl] (2a): 43 mg, yield 70%; 1H NMR (500 MHz, CDCl3, 
298 K): δ 8.69 (d, J = 5.1 Hz, 1H,), 8.14 (d, J = 8.0 Hz, 1H), 7.97 (d, J = 6.7 Hz, 1H), 
7.79 (d, J = 8.7 Hz, 1H), 7.62-7.53 (m, 5H), 7.43-7.3 (m, 4H), 1.85 (s, 3H), 1.78 (s, 3H), 
1.75 (s, 3H), 1.45 (s, 3H); 13C NMR (125 MHz, CDCl3, 298 K): δ 175.18 (JC-Rh = 33.8 
Hz), 155.32, 149.49, 140.54, 135.64, 133.83, 133.54, 131.99, 130.89, 129.71, 128.79, 
127.77, 127.21, 123.13, 121.53, 121.32, 107.6, 100.31, 95.87, 94.64, 88.79, 10.84, 
10.48, 9.54, 9.22. HR-MS (ESI): m/z calcd for [CpphRh(benzo[h]quinoline)]+: 478.1037; 
found: 478.1032; elemental analysis calcd (%) for C28H25ClRhN: C, 65.45; H, 4.90; N, 
2.73; found: C, 64.55; H, 4.86; N, 2.69.  
[CpbiphRh(benzo[h]quinoline)Cl] (3a): 41 mg, yield 58%; 1H NMR (500 MHz, CDCl3, 
298 K): δ 8.73 (d, J = 5.1 Hz, 1H,), 8.14 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 6.9 Hz, 1H), 
7.80 (d, J = 8.7 Hz, 1H), 7.68-7.55 (m, 9H), 7.48 (t, J = 7.6 Hz, 2H), 7.40-7.34 (m, 2H), 
1.89 (s, 3H),1.80 (s, 3H), 1.77 (s, 3H), 1.50 (s, 3H); 13C NMR (125 MHz, CDCl3, 298 
K): δ 175.14 (JC-Rh = 33.8 Hz), 155.30, 149.51, 140.59, 140.54, 140.31, 135.66, 133.83, 
133.53, 131.26, 131.02, 130.20, 129.71, 129.04, 127.65, 127.36, 127.21, 127.11, 
123.14, 121.59, 121.34, 107.56, 100.39, 95.44, 94.73, 88.91, 10.91, 10.53, 9.54, 9.23. 
HR-MS (ESI): m/z calcd for [CpbiphRh(benzo[h]quinoline)]+ 554.1350; found 554.1353; 
elemental analysis calcd (%) for C34H29ClRhN: C, 69.22; H, 4.95; N, 2.37; found: C, 
69.31; H, 4.96; N, 2.17. 
Synthesis of [CpXRh(benzo[h]quinoline)py]NO3 (1b-3b) 
General procedure: [CpXRh(benzo[h]quinoline)Cl] (0.05 mmol) was stirred with silver 
nitrate (0.05 mmol) in 10 ml methanol for 1.5 h. Then the solution was centrifuged and 
pyridine (0.5 mmol) was added to the upper clear layer. The colour changed from 
orange to bright yellow, and the solution was stirred 24 h. Then the solution was 
concentrated, and product recrystallized from diethyl ether giving a yellow solid which 
was dried under vacuum. 
[Cp*Rh(benzo[h]quinoline)py]NO3 (1b): 18 mg, yield 65%; 1H NMR (500 MHz, d4-
MeOD, 298 K): δ 9.44 (d, J = 5.0 Hz, 1H), 8.54 (d, J = 7.4 Hz, 1H), 8.50 (d, J = 5.6 Hz, 
2H), 8.35 (d, J = 7.2 Hz, 1H), 7.91-7.81 (m, 3H), 7.75-7.71 (m, 3H), 7.26 (t, J1 = 6.8 
Hz, J2 = 7.3 Hz, 2H), 1.65 (s, 15H); 13C NMR (125 MHz, d4-MeOD, 298 K): δ 175.14 
(JC-Rh = 35.0 Hz), 155.99, 154.20, 151.45, 141.71, 140.14, 138.82, 135.17, 134.29, 
131.98, 130.77,128.77, 127.51, 124.94, 124.35, 123.77, 98.62, 9.04. HR-MS (ESI): 
m/z calcd for [Cp*Rh(benzo[h]quinoline)pyridine]+ 495.1302, found 495.1297; 
elemental analysis calcd (%) for C28H28RhN3O3: C, 60.33; H, 5.06; N, 7.54; found: C, 
59.65; H, 4.98; N, 7.50.  
[CpphRh(benzo[h]quinoline)py]NO3 (2b): 23 mg, yield 74%; 1H NMR (500 MHz, d4-
MeOD, 298 K): δ 9.22 (d, J = 5.0 Hz, 1H,), 8.53-8.50 (m, 3H), 8.27 (d, J = 6.8 Hz, 1H), 
7.91 (d, J = 8.7 Hz, 1H), 7.82-7.74 (m, 5H), 7.30 (t, J1 = 6.7 Hz, J2 = 7.4 Hz , 2H), 7.26 
(d, J = 7.5 Hz, 1H), 7.16 (t, J1 = 7.8 Hz, J2 = 7.6 Hz, 2H), 6.90 (d, J =7.3 Hz, 2H), 1.90 
(s, 3H), 1.76 (s, 3H), 1.71 (s, 3H), 1.68 (s, 3H); 13C NMR (125 MHz, d4-MeOD, 298 K): 
δ 175.69 (JC-Rh = 33.8 Hz), 155.82, 154.29, 151.54, 141.54, 140.40, 138.98, 135.38, 
134.38, 132.14,131.63, 131.02,130.85, 129.63, 129.43, 129.02, 127.72, 125.10, 
124.27, 124.06, 105.56, 102.90, 102.08, 98.47, 93.07, 10.52, 10.35, 9.00. HR-MS 
(ESI): m/z calcd for [CpphRh(benzo[h]quinoline)pyridine]+ 557.1459, found 557.1458; 
elemental analysis calcd (%) for C33H30RhN3O3: C, 63.98; H, 4.88; N, 6.78; found: C, 
63.91; H, 4.84; N, 6.76.  
[CpbiphRh(benzo[h]quinoline)py]NO3 (3b): 22 mg, yield 63%; 1H NMR (500 MHz, d4-
MeOD, 298 K): δ 9.24 (d, J = 5.1 Hz, 1H,), 8.54 (d, J = 5.6 Hz, 2H), 8.51 (d, J = 8.0 
Hz, 1H), 8.30 (d, J = 7.0 Hz, 1H), 7.91 (d, J = 6.7 Hz, 1H), 7.83-7.74 (m, 5H), 7.53 (d, 
J = 7.4 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 7.39 (t, J1 = 7.4 Hz, J2 = 7.7 Hz, 2H), 7.33-
7.28 (m, 3H), 6.99 (d, J = 8.2 Hz, 2H),1.93 (s, 3H), 1.77 (s, 3H), 1.73 (s, 3H), 1.71 (s, 
3H); 13C NMR (125 MHz, d4-MeOD, 298 K): δ 175.67 (JC-Rh = 33.8 Hz), 155.81,154.29, 
151.59, 142.40, 141,54, 141.21,140.40, 139.00, 135.38, 134.40, 132.16, 131.55, 
130.84, 130.57, 129.97, 129.02, 128.79, 149.49, 140.54, 135.64, 133.83, 133.54, 
131.99, 130.89, 129.71, 128.79, 128.05, 127.82, 127.73, 126.12, 125.13, 124.35, 
124.07, 105.50, 102.72, 101.93, 98.28, 93.41, 10.57, 10.43, 9.02, 9.01. HR-MS (ESI): 
m/z calcd for [CpbiphRh(benzo[h]quinoline)pyridine]+ 633.1772; found 633.1768; 
elemental analysis calcd (%) for C39H34RhN3O3: C, 67.34; H, 4.93; N, 6.04; found: C, 
67.25; H, 4.86; N, 5.95. 
Methods and Instrumentation 
X-ray Crystallography: Suitable crystals were selected and mounted on a glass fibre 
with Fomblin oil and placed on an Xcalibur Gemini diffractometer with a Ruby CCD 
area detector. The crystals were kept at 150(2) K except crystal of complex 3a at 100(2) 
K during data collection. Using Olex2,[42] all the structures were solved with the 
ShelXT[43] structure solution program using direct methods and refined with the 
ShelXL[44] refinement package using least squares minimization. X-ray 
crystallographic data for complexes 2a, 3a, and 1b·PF6 have been deposited in the 
Cambridge Crystallographic Data Centre under the accession numbers CCDC 
1952984, 1952985, 1952986, respectively. X-ray crystallographic data in CIF format 
are available from the Cambridge Crystallographic Data Centre 
(http://www.ccdc.cam.ac.uk/). 
NMR Spectroscopy: 1H and 13C NMR spectroscopy and 1H-1H gs (gradient selected) 
COSY(correlation spectroscopy), 1H-13C HMQC (heteronuclear multiple quantum 
coherence) and HMBC (heteronuclear multiple bond coherence) were acquired at 298 
K (unless stated otherwise) on Bruker Advance 300 MHz, Bruker Advance III HD 500 
MHz or 600 MHz NMR spectrometers. 1H NMR chemical shifts were internally 
referenced to CHCl3 (7.26 ppm) for chloroform-d1 and (CHD2)OD (3.31 ppm) for 
methanol-d4. 13C NMR chemical shifts were internally referenced to CDCl3 (77.16 ppm) 
for chloroform-d1, and CD3OD (49.00 ppm) for methanol-d4. The data were processed 
using Mestronova and Topspin (version 2.1 Bruker UK Ltd.). 
Electrospray Mass Spectrometry: Electrospray ionization mass spectra (ESI-MS) 
were obtained by preparing the samples in methanol into a Bruker Esquire 2000 
spectrometer. The mass spectra were recorded with a scan range of m/z either 50-
500 or 400-1000 for positive ion mode. HR-MS analysis was carried with a Bruker 
MaXis plus Q-TOF mass spectrometer equipped with electrospray ionisation source. 
The mass spectrometer was operated in electrospray positive ion mode with a scan 
range 50-2,400 m/z. 
Elemental Analysis: CHN elemental analyses were carried out on a CE-440 
elemental analyzer by Warwick Analytical (UK) Ltd. 
pH measurements: pH or pH* (pH meter reading without correction for effect of 
deuterium on glass electrode) values of samples in H2O or D2O were measured at ca. 
298 K, using a HATCH minilab pocket pH meter with ISFET (silicon chip non-glass pH 
sensor) sensor, calibrated with buffer solutions included of pH 4, 7, and 10. 
UV-Vis spectroscopy: A Cary 300 UV-Vis recording spectrophotometer was used 
with 1 cm path-length quartz cuvettes (3.0 mL) and a PTP1 Peltier temperature 
controller. Experiments were carried out at 310 K from 800 to 200 nm in 0.5 nm 
intervals unless stated otherwise. Spectra were recorded using UV Winlab software 
and analysed using Origin 2018. 
Reactions with NADH: The time dependence of reactions of rhodium complexes (0.8 
µM) with NADH (75-144 µM) were studied over 24 h in 1.6% MeOH-98.4% phosphate 
buffer (5 mM, pH 7.4) by UV-vis spectroscopy at 310 K. The concentration of NADH 
was obtained using the extinction coefficient ε(339 nm) = 6,220 M-1cm-1.[31] TON was 
calculated from the difference in NADH concentration divided by the concentration of 
metal complex catalyst over 24 h. TOF was calculated from the linear fitting of TON 
versus time (h) by Origin 2018.  
ICP-OES: ICP-OES analysis was carried out on a PerkinElmer Optima 5300 DV series 
Optical Emission Spectrophotometer. The Rhodium Specpure® plasma standard (Alfa 
Aesar, 1000 pm in 10% HCl) was diluted with ca. 3.6% HNO3 Milli-Q water to provide 
freshly prepared calibrants at concentrations of 700, 600, 500, 400, 300, 200, 100, 50, 
and 0 ppb, which were adjusted to match the sample matrix by standard addition of 
sodium chloride (TraceSELECT®). Total dissolved solids did not exceed 0.2% w/v. 
Data were acquired and processed using WinLab32 V3.4.1 for Windows. 
ICP-MS: The whole cell pellet was digested in 72% nitric acid at 353 K overnight. 
Samples after digestion were diluted to give a final concentration of ca. 3.6% nitric 
acid and analysed using an ICP-MS Agilent Technologies 7500 series in no-
gas/helium mode. ICP-MS TOP and Offline Data Analysis (ChemStation version 
B.03.05) by Agilent Technologies were used to process the data. Biological triplicates 
were produced for each sample and statistical significance was calculated (Welch’s 
unpaired t-test). 
High-Performance Liquid Chromatography (HPLC)/LC-MS: Reverse phase HPLC 
(RP-HPLC) was performed on a HP 1100 Series HPLC System (Agilent) using a 
ZORBAX Eclipse Plus C-18 column (250 x 4.6 mm, 5 µm). Eluents: A-water (0.1% v/v 
TFA), B-acetonitrile (0.1% v/v TFA). Solvent gradient method: 0-30 min, 10%-80% B; 
30-40 min, 80% B; 40-41 min, 80%-10% B; 40-55 min, 10% B. A flow rate of 1 mL min-
1 was used with detection wavelength at 254 nm. LC-MS was carried out on a Bruker 
Amazon X connected online to an Agilent 1260 HPLC with detection wavelength 254 
nm. The mobile phases and the solvent gradient method were the same as HPLC. 
Cell Culture: A549 human lung cell line and A2780 human ovarian cell line were 
grown in RPMI-1640 with L-glutamine supplemented with 10% v/v fetal bovine serum, 
and 1% v/v penicillin/streptomycin. All cells were grown as adherent monolayers at 
310 K with 5% CO2 humidified, and were passaged at ca. 80% confluency. 
Cell Viability Assay: Briefly, 5000 cells were seeded per well in 96-well plates. The 
cells were pre-incubated in drug-free media at 310 K for 48 h before adding different 
concentrations of test compounds. Stock solutions of the complexes were prepared in 
DMSO (<0.5%)/cell culture medium and the concentration of each metal complex in 
the stock solution was determined by ICP-OES. The drug exposure period was 24 h. 
After this, supernatants were removed by suction and each well was washed with 100 
µL PBS. The cells were allowed a further 72 h recovery in free fresh medium at 310 
K. SRB assay was used to determine cell viability.[45] Absorbance measurements of 
the solubilized dye (on a BioRad iMark microplate reader using a 470 nm filter) allowed 
the determination of viable treated cells compared to untreated controls. IC50 values 
were determined as duplicates of triplicates in two independent sets of experiments 
and their standard deviations were calculated. 
Cellular Rh Accumulation: The accumulation of Rh in A549 human lung carcinoma 
cells was determined by ICP-MS (Inductively Coupled Plasma Mass Spectroscopy). 
1x106 cells were seeded into a 100 mm Petri dish and incubated in drug-free media for 
24 h at 310 K with 5% CO2. For a further 24 h, the cells were incubated in media 
containing 0.5× and 1 × IC50 concentrated complex 3a or 3b. Following this, cells 
were washed, detached using trypsin-EDTA, resuspended in fresh media, counted 
and centrifuged. The cell pellets were digested as ICP-MS protocol for Rh analysis.  
ROS Determination: 5×104 A549 human lung carcinoma cells were seeded per well 
in a 6-well plate and incubated for 24 h at 310 K. 1× or 2× IC50 concentrated complex 
3a or 3b was added to the cells and incubated for a further 24 h. After which, total 
ROS and SO concentrations were analysed by flow cytometry using the total 
ROS/superoxide detection kit by Enzo Life Sciences. Briefly, the cells were 
enzymatically detached using trypsin-EDTA, washed in PBS, resuspended in staining 
solution, prepared according to manufacturer’s instructions (25 nM concentration of 
both dyes, total ROS and SO) and incubated at room temperature for 30 min. Samples 
were then analysed on the Beckton Dickinson LSRII using Beckton Dickinson 
FACSDIVA software. Data were processed using flowjo V10 for Windows. At all times, 
samples were kept under dark conditions to avoid light-induced ROS production. 
Welch’s t-tests were carried out to establish statistical significance of the variations. 
Apoptosis Assay: 5×104 A549 human lung carcinoma cells were seeded per well in 
a 6-well plate and incubated for 24 h at 310 K. 1× or 2× IC50 concentrated complex 
3a or 3b was added to the cells and incubated for a further 24 h. After which, the cells 
were enzymatically detached using trypsin-EDTA, washed in PBS, resuspended in 
staining solution (FITC Annexin V diluted 1 in 100 and 1 µg/mL PI) and incubated at 
room temperature for 30 min. Samples were then analysed on the Beckton Dickinson 
LSRII using Beckton Dickinson FACSDIVA software. Data was processed using flowjo 
V10 for Windows. Welch’s t-tests were carried out to establish statistical significance 
of the variations. 
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Text for Table of Contents: 
The chemical reactivity and cytotoxicity of such organo-rhodium compounds can be 
controlled by the nature of the monodentate ligand (chloride or pyridine). Compared 
to the pyridine analogues, the chloride compounds show faster hydrolysis and higher 
catalysis efficiency. However, the pyridine compounds exhibit higher cytotoxicity 
(lower IC50 values) with lower cellular Rh accumulation. More interestingly, the pyridine 
complexes appear to act as ROS scavengers, while the chloride analogues induce 
ROS elevation in cancer cells. 
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